SRR11296849
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V2+0.380
- MITOTIC_SPINDLE+0.310
- NOTCH_SIGNALING+0.220
- SPERMATOGENESIS+0.160
- UNFOLDED_PROTEIN_RESPONSE+0.100
- PANCREAS_BETA_CELLS+0.050
- MYC_TARGETS_V1+0.030
- WNT_BETA_CATENIN_SIGNALING+0.030
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.500
- INTERFERON_ALPHA_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- COMPLEMENT-0.410
- IL6_JAK_STAT3_SIGNALING-0.400
- HYPOXIA-0.380
- KRAS_SIGNALING_UP-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- INFLAMMATORY_RESPONSE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208946 | — | — | 0.926 |
| 2 | SRR8518301 | — | E | 0.916 |
| 3 | SAMN03290891 | — | — | 0.912 |
| 4 | BS_M0QYNVK8 | high-grade glioma | — | 0.909 |
| 5 | BS_KABQQA0T | Diffuse intrinsic pontine glioma | — | 0.907 |
| 6 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.904 |
| 7 | BS_Y8D1F5WW | medulloblastoma | — | 0.904 |
| 8 | C3L-04013 | — | cohortMD1 | 0.903 |
| 9 | TCGA-98-A53A-01A-11R-A262-07 | — | cohortSQ1 | 0.900 |
| 10 | SRR5088819 | — | — | 0.900 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.030 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.020 | Remibrutinib | — uncovered |